Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 72162-2212

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 72162-2212). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Clopidogrel Fig)

A figure showing the exposure to Clopidogrel active metabolite after multiple 75 mg doses alone or with proton pump inhibitors (PPIs). It illustrates the effect on active metabolite AUC with mean and 90% confidence intervals for dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg, relative to clopidogrel administered alone.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A cumulative event rate line graph showing cardiovascular death, myocardial infarction, and stroke rates over 12 months of follow-up comparing Clopidogrel (+ aspirin) versus placebo (+ aspirin). The graph plots cumulative event rate (%) on the y-axis and months of follow-up on the x-axis, with Clopidogrel showing consistently lower event rates than placebo.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

A forest plot chart showing hazard ratios with 95% confidence intervals for Clopidogrel versus Placebo across various subgroups by age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, heparin/LMWH use, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The plot indicates whether each subgroup favors Clopidogrel or Placebo based on the hazard ratios displayed as diamond markers along a horizontal axis ranging from 0.3 to 1.4.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A line graph titled 'Cumulative Event Rates for Death in the COMMIT Study' showing the percentage of patients who died before first discharge over 28 days since randomization. It compares placebo and Clopidogrel groups, reporting 8.1% deaths in placebo and 7.5% in Clopidogrel, with a noted 7% proportional risk reduction (p=0.03). A note states all treated patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A line chart showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. The chart compares two groups: placebo (10.1% event rate) and clopidogrel (9.2% event rate), indicating a 9% proportional risk reduction with clopidogrel (p=0.002). The vertical axis represents percentage, and the horizontal axis represents days since randomization up to 28 days.*

FDA Label Image

Figure6 (Clopidogrel Fig6)

Figure 6 shows a forest plot depicting the effects of adding Clopidogrel to Aspirin on the combined primary endpoint across baseline and concomitant medication subgroups in the COMMIT study. The plot includes subgroups by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, with odds ratios and confidence intervals comparing Clopidogrel versus placebo outcomes.*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A line graph displaying the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up. Two lines compare the event rates for aspirin and clopidogrel, showing slightly lower rates for clopidogrel. The graph includes a p-value of 0.045 indicating statistical comparison.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A forest plot titled "Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study" showing hazard ratios for clopidogrel versus aspirin across subgroups: Stroke, MI, PAD, and Overall. The x-axis represents hazard ratios from 0.6 to 1.3, with markers and confidence intervals indicating relative favorability towards clopidogrel or aspirin.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure diagram of the active ingredient clopidogrel bisulfate, showing molecular bonds and functional groups including a thiophene ring, piperidine ring, and ester group with sulfate salt indicated.*

FDA Label Image

Label (Lbl721622212)

Label for Clopidogrel Tablets, USP 75 mg film-coated tablets. The label indicates the product is relabeled by Bryant Ranch Prepack and manufactured by ScieGen Pharmaceuticals. The package contains 1000 tablets and includes storage instructions and medication guide dispensing information, along with a barcode and an NDC number 72162-2212-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.